Poop pills could ease stomach troubles for scleroderma patients

NCT ID NCT06333795

Ongoing Symptom relief Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether fecal microbiota transplantation (FMT) – giving healthy donor stool in capsules – can safely reduce chronic diarrhea in people with systemic sclerosis. Twenty adults with scleroderma and persistent diarrhea will receive either FMT or a placebo. The main goal is to check for side effects, with a secondary look at whether symptoms improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplantation (FMT) given as capsules
What this could lead to: If it works, this could offer a new, safe way to manage chronic diarrhea in people with systemic sclerosis, improving daily comfort and quality of life.
What could go wrong: This is a very small, early pilot study with only 20 people. It mainly checks safety, not whether FMT truly works. Results may not apply to everyone with scleroderma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIARRHEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diarrheal disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIARRHEA SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Aarhus University Hospital

Aarhus, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.